JP2010535504A - クラミジア抗原 - Google Patents

クラミジア抗原 Download PDF

Info

Publication number
JP2010535504A
JP2010535504A JP2010519930A JP2010519930A JP2010535504A JP 2010535504 A JP2010535504 A JP 2010535504A JP 2010519930 A JP2010519930 A JP 2010519930A JP 2010519930 A JP2010519930 A JP 2010519930A JP 2010535504 A JP2010535504 A JP 2010535504A
Authority
JP
Japan
Prior art keywords
fragment
amino acid
seq
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010519930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535504A5 (enExample
Inventor
ヒギンス，ダレン，イー．
ギーラーン，トッド
スターンバック，マイケル，エヌ．
ローン，ナディア，アール．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2010535504A publication Critical patent/JP2010535504A/ja
Publication of JP2010535504A5 publication Critical patent/JP2010535504A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010519930A 2007-08-03 2008-08-01 クラミジア抗原 Pending JP2010535504A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96321507P 2007-08-03 2007-08-03
PCT/US2008/009282 WO2009020553A2 (en) 2007-08-03 2008-08-01 Chlamydia antigens

Publications (2)

Publication Number Publication Date
JP2010535504A true JP2010535504A (ja) 2010-11-25
JP2010535504A5 JP2010535504A5 (enExample) 2012-10-11

Family

ID=40341938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010519930A Pending JP2010535504A (ja) 2007-08-03 2008-08-01 クラミジア抗原

Country Status (7)

Country Link
US (1) US20100260791A1 (enExample)
EP (1) EP2185577A4 (enExample)
JP (1) JP2010535504A (enExample)
CN (1) CN102027003A (enExample)
AU (1) AU2008284352A1 (enExample)
CA (1) CA2695421A1 (enExample)
WO (1) WO2009020553A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020115870A (ja) * 2012-12-28 2020-08-06 セルスティス リミテッド 細胞媒介免疫応答アッセイ

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
CA2728927C (en) 2008-07-01 2018-02-13 Genocea Biosciences, Inc. Antigen screening system
CA2835630A1 (en) 2011-05-11 2012-11-15 Richard Malley Modified biotin-binding protein, fusion proteins thereof and applications
SG11201908530QA (en) 2017-03-20 2019-10-30 Genocea Biosciences Inc Treatment methods
WO2019014519A1 (en) * 2017-07-13 2019-01-17 Nanobio Corporation ANTI-CHLAMYDIA VACCINE IN THE FORM OF NANOEMULSION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028475A2 (en) * 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
ES2312649T3 (es) * 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0203403D0 (en) * 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
JP4896715B2 (ja) * 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
CA2633142A1 (en) * 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, S.R.L. Chlamydial antigens
WO2008156729A2 (en) 2007-06-14 2008-12-24 Emergent Product Development Gaithersburg Inc. Vaccines against chlamydia infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028475A2 (en) * 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013033461; Ｓｔｅｐｈｅｎｓ，Ｒ．Ｓ．，ｅｔ　ａｌ．: 'Ａｃｃｅｓｓｉｏｎ　ｎｏ．Ｏ８４１４６，Ｈｙｐｏｔｈｅｔｉｃａｌ　ｐｒｏｔｅｉｎ' ＮＣＢＩ　Ｐｒｏｔｅｉｎ　ＤＢ［ｏｎｌｉｎｅ］，３１-ＯＣＴ-２００６［ｒｅｔｒｉｅｖｅｄ　ｏｎ　１　Ｊｕｌ　２０１３］ *
JPN6013033463; Ｊ　Ｃｌｉｎ　Ｍｉｃｒｏｂｉｏｌ．（２００７），Ｖｏｌ．４５，Ｎｏ．５，ｐ．１４１０-１４１４ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020115870A (ja) * 2012-12-28 2020-08-06 セルスティス リミテッド 細胞媒介免疫応答アッセイ
JP7008739B2 (ja) 2012-12-28 2022-01-25 セルスティス リミテッド 細胞媒介免疫応答アッセイ

Also Published As

Publication number Publication date
AU2008284352A1 (en) 2009-02-12
WO2009020553A3 (en) 2009-04-09
US20100260791A1 (en) 2010-10-14
EP2185577A4 (en) 2010-09-22
WO2009020553A2 (en) 2009-02-12
CN102027003A (zh) 2011-04-20
EP2185577A2 (en) 2010-05-19
AU2008284352A2 (en) 2010-05-27
CA2695421A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
US9115185B2 (en) Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US20170348410A1 (en) Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US7507538B2 (en) Human papilloma virus immunoreactive peptides
US20070014810A1 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP5888823B2 (ja) 皮内ｈｐｖペプチドワクチン接種
JP4519461B2 (ja) 免疫学的に重要な単純ヘルペスウイルス抗原およびそれを用いる方法
JP2010535504A (ja) クラミジア抗原
US20040191270A1 (en) Vaccine compositions
JP2012512257A (ja) クラミジア抗原およびその使用
TW202334198A (zh) 用於避免感染與治療遠程新冠肺炎之針對SARS-CoV-2 OMICRON BA.4/BA.5的疫苗組成物
CA2536735C (en) Methods for determining cd8+ t-cell epitopes
CN112867502A (zh) Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗
KR20050050115A (ko) 유두종바이러스의 2종 이상의 비구조적 초기 단백질을암호화하는 ｄｎａ 백신
US8637053B2 (en) Chlamydia antigens
KR20240011134A (ko) Rsv 및 piv3 감염을 예방하기 위한 조성물 및 방법
JP2004522789A (ja) 乳頭腫ウイルスワクチン
US11344614B2 (en) Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
AU2002258614B8 (en) Human papilloma virus immunoreactive peptides
EP2331104A2 (en) Method of inducing an anti-viral immune response
AU2002258614A1 (en) Human papilloma virus immunoreactive peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110801

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131003

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150310